Cardiff Oncology, Inc.

DB:XE7C Stock Report

Market Cap: €123.1m

Cardiff Oncology Valuation

Is XE7C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XE7C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XE7C's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XE7C's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XE7C?

Key metric: As XE7C barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for XE7C. This is calculated by dividing XE7C's market cap by their current book value.
What is XE7C's PB Ratio?
PB Ratio2.6x
BookUS$49.39m
Market CapUS$129.88m

Price to Book Ratio vs Peers

How does XE7C's PB Ratio compare to its peers?

The above table shows the PB ratio for XE7C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
HPHA Heidelberg Pharma
3.1x-33.0%€110.9m
2INV 2invest
1xn/a€64.4m
FYB Formycon
1.5x32.4%€882.8m
BIO3 Biotest
2x29.3%€1.3b
XE7C Cardiff Oncology
2.6x-27.9%€129.9m

Price-To-Book vs Peers: XE7C is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does XE7C's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
XE7C 2.6xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: XE7C is expensive based on its Price-To-Book Ratio (2.6x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is XE7C's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XE7C PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XE7C's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XE7C forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.53
€8.54
+237.7%
25.0%€12.13€6.53n/a4
Nov ’25€2.83
€8.48
+200.3%
28.9%€12.63€6.31n/a4
Oct ’25€2.32
€8.48
+265.7%
28.9%€12.63€6.31n/a4
Sep ’25€2.00
€9.05
+352.8%
30.3%€12.82€6.41n/a3
Aug ’25€2.09
€9.13
+337.9%
30.6%€13.00€6.50n/a3
Jul ’25€1.91
€9.13
+378.1%
30.6%€13.00€6.50n/a3
Jun ’25€2.86
€9.13
+219.3%
30.6%€13.00€6.50n/a3
May ’25€4.09
€9.08
+122.3%
30.2%€12.85€6.42n/a3
Apr ’25€4.93
€9.08
+84.3%
30.2%€12.85€6.42n/a3
Mar ’25€2.02
€8.51
+321.5%
22.5%€11.07€6.46n/a3
Feb ’25€1.41
€7.88
+460.3%
34.2%€11.30€4.71n/a3
Jan ’25€1.27
€7.88
+519.3%
34.2%€11.30€4.71n/a3
Dec ’24€1.09
€7.88
+622.8%
34.2%€11.30€4.71n/a3
Nov ’24€0.98
€7.97
+709.8%
34.0%€11.36€4.73€2.833
Oct ’24€1.28
€7.20
+461.7%
38.1%€11.42€4.76€2.324
Sep ’24€1.66
€6.91
+316.3%
38.1%€10.96€4.57€2.004
Aug ’24€1.57
€7.30
+365.4%
53.0%€12.77€4.56€2.093
Jul ’24€1.30
€7.30
+461.3%
53.0%€12.77€4.56€1.913
Jun ’24€1.48
€7.30
+391.7%
53.0%€12.77€4.56€2.863
May ’24€1.54
€7.64
+397.6%
56.6%€13.76€4.59€4.093
Apr ’24€1.49
€8.28
+455.8%
47.4%€14.22€4.74€4.934
Mar ’24€1.62
€8.58
+430.3%
44.4%€14.16€5.06€2.024
Feb ’24€1.63
€8.58
+427.1%
44.4%€14.16€5.06€1.414
Jan ’24€1.25
€8.58
+587.5%
44.4%€14.16€5.06€1.274
Dec ’23€1.43
€8.58
+499.4%
44.4%€14.16€5.06€1.094
Nov ’23€1.60
€8.58
+435.5%
44.4%€14.16€5.06€0.984

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%